PROSPECTIVE EFFICACY STUDY OF A SELF-ADMINISTERED ALLERGEN-IMMUNOTHERAPY PROTOCOL

Autor: W. Wagoner, Thomas C. Hulsey, Myla Ebeling, Frederick M. Schaffer
Rok vydání: 2018
Předmět:
Zdroj: Annals of Allergy, Asthma & Immunology. 121:S27
ISSN: 1081-1206
DOI: 10.1016/j.anai.2018.09.083
Popis: Introduction We have previously demonstrated the safety of a self-administered subcutaneous immunotherapy protocol (SCIT; IFAR 2015;5:149-156). Here we report the preliminary results of our IRB approved prospective efficacy study. Methods Subjects that met the inclusion criteria and chose SCIT therapy constituted the treatment group (N=54). Those that deferred SCIT therapy constituted the control group (N=28). All patients were studied and were on therapy for a mean of 32 months. The study primary outcome measure was the combined symptom plus medication scores (SS+MS). The secondary outcome measure was the rhinoconjuctivitis quality of life (RQLQ) scores. Statistical assessment utilized the student and paired T-test. Results The study groups were well matched as manifested by baseline measures that demonstrated no significant differences. Patient groups were compared based on common aeroallergen allergies, season, and relevant pollen counts. Treatment patient analyses showed significant improvement (41-56%) compared to baseline indices for SS, MS, SS+MS and RQLQ. In contrast, control group indices demonstrated little to no improvement. Treatment group results demonstrated improvements of 57% (57% (SS, p Conclusions These results demonstrate that the self-administered SCIT protocol used in this study produced significant and clinically relevant improvement. When contrasted with office-based SCIT studies, our efficacy was found to be equivalent.
Databáze: OpenAIRE